



**BIOALPHA HOLDINGS BERHAD**  
(Registration No: 201101021398 (949536-X))  
**(“BHB” OR THE “COMPANY”)**

**INTERIM FINANCIAL REPORT FOR THE  
THIRD (3rd) QUARTER ENDED 30 SEPTEMBER 2025**

<b>Contents</b>	<b>Page</b>
Unaudited Condensed Consolidated Statement of Comprehensive Income	1
Unaudited Condensed Consolidated Statement of Financial Position	2
Unaudited Condensed Consolidated Statement of Changes in Equity	4
Unaudited Condensed Consolidated Statement of Cash Flows	6
Notes to the Unaudited Condensed Consolidated Financial Statements	9

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME FOR THE THIRD (3rd) QUARTER ENDED 30 SEPTEMBER 2025**

	<--- Individual Quarter ---->		<---- Cumulative Quarter ---->	
	Unaudited 30 Sep 2025 RM'000	Unaudited 30 Sep 2024 RM'000	Unaudited 30 Sep 2025 RM'000	Unaudited 30 Sep 2024 RM'000
Revenue	2,960	34,934	8,237	65,118
Cost of sales	(3,036)	(34,780)	(9,678)	(64,879)
Gross (loss)/profit	(76)	154	(1,441)	239
Other incomes	470	3,822	1,375	5,439
Administrative expenses	(3,772)	(7,977)	(8,466)	(19,720)
Net loss on impairment of financial assets	(1,462)	(2,188)	(11,314)	(6,116)
Loss from operations	(4,840)	(6,189)	(19,846)	(20,158)
Finance costs	(48)	(124)	(202)	(442)
Loss before taxation	(4,888)	(6,313)	(20,048)	(20,600)
Taxation	-	(1)	150	(3)
Share of profit/(loss) of associated company	15	(34)	23	(36)
Loss for the financial period	(4,873)	(6,348)	(19,875)	(20,639)
Other comprehensive income/(loss)				
- Exchange differences on translation of foreign operation	425	(3,034)	(930)	(3,832)
Total comprehensive loss for the period	(4,448)	(9,382)	(20,805)	(24,471)
Loss for the financial period attributable to:				
- Owners of the parent	(4,820)	(5,597)	(19,633)	(19,888)
- Non-controlling interests	(53)	(751)	(242)	(751)
	(4,873)	(6,348)	(19,875)	(20,639)
Total comprehensive loss attributable to:				
- Owners of the parent	(4,488)	(8,887)	(20,611)	(23,302)
- Non-controlling interests	40	(495)	(194)	(1,169)
	(4,448)	(9,382)	(20,805)	(24,471)
Loss per share attributable to owners of the parent (sen):				
- Basic	(0.343)	(0.398)	(1.396)	(1.414)
- Diluted	(0.312)	(0.362)	(1.269)	(1.286)

**Notes:**

The unaudited condensed consolidated statement of comprehensive income should be read in conjunction with the Audited Financial Statements of BHB for the financial year ended ("FYE") 31 December 2024 and the accompanying explanatory notes attached to this interim financial report.

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 SEPTEMBER 2025**

	<b>Unaudited As at 30 Sep 2025 RM'000</b>	<b>Audited As at 31 Dec 2024 RM'000</b>
<b>NON-CURRENT ASSETS</b>		
Property, plant and equipment	29,336	32,875
Intangible assets	34,679	37,634
	<u>64,015</u>	<u>70,509</u>
<b>CURRENT ASSETS</b>		
Biological assets	170	95
Inventories	3,558	3,699
Trade receivables	1,412	1,044
Other receivables	1,921	1,650
Tax recoverable	311	297
Other investments	14,326	25,966
Fixed deposits with licensed banks	2,155	3,631
Cash and bank balances	3,371	7,160
	27,224	43,542
Assets of disposal group classified as held for sale	-	4,940
	<u>27,224</u>	<u>48,482</u>
<b>TOTAL ASSETS</b>	<b><u>91,239</u></b>	<b><u>118,991</u></b>
<b>EQUITY</b>		
Share capital	76,192	186,191
ICPS	2,889	2,890
Reserves	(1,348)	(90,736)
<b>Equity attributable to owners of the parent</b>	<u>77,733</u>	<u>98,345</u>
Non-controlling interests	(822)	(629)
<b>TOTAL EQUITY</b>	<u>76,911</u>	<u>97,716</u>
<b>NON-CURRENT LIABILITIES</b>		
Lease liabilities	1,777	3,727
Bank borrowings	514	595
Deferred tax liabilities	3,864	3,864
	<u>6,155</u>	<u>8,186</u>

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 SEPTEMBER 2025 (CONT'D)**

	<b>Unaudited As at 30 Sep 2025 RM'000</b>	<b>Audited As at 31 Dec 2024 RM'000</b>
<b>CURRENT LIABILITIES</b>		
Trade payables	468	1,918
Other payables	3,377	3,873
Contract liabilities	1,735	1,533
Lease liabilities	2,269	618
Bank borrowings	324	387
	8,173	8,329
Liabilities of disposal group classified as held for sale	-	4,760
	<u>8,173</u>	<u>13,089</u>
<b>TOTAL LIABILITIES</b>	<u>14,328</u>	<u>21,275</u>
<b>TOTAL EQUITY AND LIABILITIES</b>	<u><b>91,239</b></u>	<u><b>118,991</b></u>
<b>NET ASSETS PER SHARE (sen)</b>	5.47 <sup>(1)</sup>	7.75 <sup>(2)</sup>

*Notes:*

(1) Based on 1,406,494,277 ordinary shares in BHB as at 30 September 2025.

(2) Based on 1,406,491,096 ordinary shares in BHB as at 31 December 2024.

*The unaudited condensed consolidated statement of financial position should be read in conjunction with the Audited Financial Statements of BHB for the FYE 31 December 2024 and the accompanying explanatory notes attached to this interim financial report.*

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE THIRD (3rd ) QUARTER ENDED 30 SEPTEMBER 2025

	Attributable to owners of the Company							Non-Distributable		
	Share Capital	ICPS	Warrant Reserve	SIS Option Reserve	Merger Deficits	Foreign Currency Translation Reserve	Accumulated losses	Total	Non-Controlling Interests	Total Equity
	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000
Balance as at 1 January 2024	186,191	2,890	-	803	(4,569)	3,687	(61,634)	127,368	2,265	129,633
<b>Continuing operations</b>										
Loss for the financial year	-	-	-	-	-	-	(54,397)	(54,397)	(1,941)	(56,338)
Acquisition of non-controlling interest	-	-	-	-	-	-	-	-	(97)	(97)
Disposal of a subsidiary	-	-	-	-	-	-	-	-	(1,083)	(1,083)
Exchange differences on translation of foreign operation	-	-	-	-	-	1,117	-	1,117	227	1,344
<b>Total comprehensive loss</b>	-	-	-	-	-	1,117	(54,397)	(53,280)	(2,893)	(56,174)
<b>Discontinuing operations</b>										
Loss for the financial year	-	-	-	-	-	-	5,844	5,844	-	5,844
<b>Total comprehensive loss</b>	-	-	-	-	-	-	5,844	5,844	-	5,844
<b>Transactions with owners</b>										
Issuance of warrants	-	-	18,413	-	-	-	-	18,413	-	-
	-	-	18,413	-	-	-	-	18,413	-	18,413
<b>Balance as at 31 December 2024</b>	<b>186,191</b>	<b>2,890</b>	<b>18,413</b>	<b>803</b>	<b>(4,569)</b>	<b>4,804</b>	<b>(110,187)</b>	<b>98,345</b>	<b>(629)</b>	<b>97,716</b>

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE THIRD (3rd) QUARTER ENDED 30 SEPTEMBER 2025 (CONT'D)

	<----- Attributable to owners of the Company ----->						<----- Non-Distributable ----->			
	Share Capital	ICPS	Warrant Reserve	SIS Option Reserve	Merger Deficits	Foreign Currency Translation Reserve	Accumulated losses	Total	Non- Controlling Interests	Total Equity
	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000
Balance as at 1 January 2025	186,191	2,890	18,413	803	(4,569)	4,804	(110,187)	98,345	(629)	97,716
Loss for the financial year	-	-	-	-	-	-	(19,633)	(19,633)	(242)	(19,875)
Exchange differences on translation of foreign operation	-	-	-	-	-	(979)	-	(979)	49	(930)
<b>Total comprehensive loss</b>	-	-	-	-	-	(979)	(19,633)	(20,612)	(193)	(20,805)
<b>Transactions with owners</b>										
Conversion of ICPS	1	(1)	-	-	-	-	-	-	-	-
Shares capital reduction	(110,000)	-	-	-	-	-	110,000	-	-	-
	(109,999)	(1)	-	-	-	-	110,000	-	-	-
<b>Balance as at 30 September 2025</b>	<b>76,192</b>	<b>2,889</b>	<b>18,413</b>	<b>803</b>	<b>(4,569)</b>	<b>3,825</b>	<b>(19,820)</b>	<b>77,733</b>	<b>(822)</b>	<b>76,911</b>

*Note:*

*The unaudited condensed consolidated statement of changes in equity should be read in conjunction with the audited financial statements of BHB for the FYE 31 December 2024 and the accompanying explanatory notes attached to this interim financial report.*

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE THIRD (3rd) QUARTER ENDED 30 SEPTEMBER 2025**

	<b>Unaudited Current Period to date 30 Sep 2025 RM'000</b>	<b>Unaudited Preceding Corresponding Period to date 30 Sep 2024 RM'000</b>
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Loss before taxation	(20,048)	(20,600)
<b>Adjustments for:</b>		
Amortisation of intangible assets	1,426	2,059
Amortisation of deferred capital grant	(3)	(20)
Amortisation of biological assets and bearer plant	18	4
Amortisation of right-of-use assets	335	974
Bad debt written off	-	7,015
Deposit written off	11	-
Depreciation of property, plant and equipment	3,162	5,528
Fair value gain on biological assets	(75)	(19)
Fair value loss on quoted shares investments	11,641	6,440
Gain on disposal of subsidiary	(865)	(44)
Gain on disposal of property, plant and equipment	(119)	(1,810)
Impairment losses on intangible assets	1,318	-
Impairment losses on investment in associate	23	-
Impairment losses on property, plant and equipment	-	843
Interest expense	202	442
Interest income	(57)	(186)
Inventories written off	-	552
Property, plant and equipment written off	115	-
Reversal of impairment losses on other receivables	(59)	(271)
Reversal of impairment losses on trade receivables	(193)	(6,725)
Reversal of provision of slow-moving inventories	-	(533)
Unrealised (gain)/loss on foreign exchange	(14)	210
Operating loss before working capital changes	(3,181)	(6,140)
<b>Changes in working capital:</b>		
Bill payables	(112)	93
Contract liabilities	556	315
Inventories	141	(12)
Trade receivables	(359)	1,830
Other receivables	(567)	1,377
Trade payables	(1,450)	305
Other payables	(848)	4,933
Cash (used in)/from operations	(5,820)	2,701

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE THIRD (3rd)  
QUARTER ENDED 30 SEPTEMBER 2025 (CONT'D)**

	<b>Unaudited Current Period to date 30 Sep 2025 RM'000</b>	<b>Unaudited Preceding Corresponding Period to date 30 Sep 2024 RM'000</b>
<b>CASH FLOWS FROM OPERATING ACTIVITIES (CONT'D)</b>		
Interest paid	(24)	(121)
Interest received	57	186
Tax paid	(40)	(56)
Tax refund	176	(1)
<b>NET CASH (USED IN)/FROM OPERATING ACTIVITIES</b>	<b>(5,651)</b>	<b>2,709</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Increase in quoted shares investment	-	(11,683)
Net placement of fixed deposits	-	(500)
Purchase of property, plant and equipment	(393)	(2,437)
Proceeds from disposal of property, plant and equipment	189	2,134
Proceeds from disposal of subsidiary companies	180	144
Net cash outflows arising from disposal of subsidiary	(48)	(197)
<b>NET CASH USED IN INVESTING ACTIVITIES</b>	<b>(72)</b>	<b>(12,539)</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
(Increase)/decrease in fixed deposit pledged and maturity more than 3 months	(24)	87
Drawdown of lease liabilities	-	280
Repayment of lease liabilities	(558)	(982)
Repayment of term loans	(33)	(3,426)
Proceeds from issue of warrant	-	18,413
Interest paid	(126)	(309)
<b>NET CASH (USED IN)/FROM FINANCING ACTIVITIES</b>	<b>(741)</b>	<b>14,063</b>

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE THIRD (3rd) QUARTER ENDED 30 SEPTEMBER 2025 (CONT'D)**

	<b>Unaudited Current Period to date 30 Sep 2025 RM'000</b>	<b>Unaudited Preceding Corresponding Period to date 30 Sep 2024 RM'000</b>
<b>NET (DECREASE)/ INCREASE IN CASH AND CASH EQUIVALENTS</b>	(6,464)	4,233
<b>EFFECT OF EXCHANGE TRANSLATION DIFFERENCES</b>	1,128	(1,882)
<b>CASH AND CASH EQUIVALENTS AT BEGINNING OF THE FINANCIAL PERIOD</b>	7,207	10,424
<b>CASH AND CASH EQUIVALENTS AT END OF THE FINANCIAL PERIOD</b>	1,871	12,775
<b>CASH AND CASH EQUIVALENTS AT END OF THE FINANCIAL PERIOD COMPRISES:</b>		
Cash and bank balances	3,371	7,075
Fixed deposits with licensed banks	2,155	7,131
	5,526	14,206
Less: Fixed deposits pledged with licensed banks	(1,455)	(1,431)
Less: Fixed deposits maturity more than 3 months	(2,200)	-
	1,871	12,775

*Note:*

*The unaudited condensed consolidated statement of cash flows should be read in conjunction with the audited financial statements of BHB for the FYE 31 December 2024 and the accompanying explanatory notes attached to this interim financial report.*

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THIRD (3RD) QUARTER ENDED 30 SEPTEMBER 2025**

**A. EXPLANATORY NOTES TO THE UNAUDITED CONSOLIDATED INTERIM FINANCIAL REPORT FOR THE THIRD (3RD) QUARTER ENDED 30 SEPTEMBER 2025**

**A1. Accounting policies and methods of computation**

The condensed consolidated interim financial statements are unaudited and have been prepared in accordance with the Malaysian Financial Reporting Standards (“**MFRS**”) 134: Interim Financial Reporting, paragraph 9.22 and Appendix 9B of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad (“**Bursa Securities**”) (“**Listing Requirements**”).

The condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the FYE 31 December 2024 and the accompanying explanatory notes attached to this interim financial report.

The financial information presented herein has been prepared in accordance with the accounting policies to be used in preparing the annual consolidated financial statements for the FYE 31 December 2024 under the MFRS framework. These policies do not differ significantly from those used in the audited consolidated financial statements for the FYE 31 December 2024 except as disclosed below:

**Standard and amendments to published standards that are effective**

On 1 January 2025, the Group applied the following new published standard and amendments to published standards:

- Amendments to MFRS 121, The Effects of Changes in Foreign Exchange Rates: Lack of Exchangeability

The adoption of the above amendments to published standards did not have any significant impact on the current period or any prior period and is not likely to affect future periods.

**Standards issued but not yet effective:**

The following are accounting standards, amendments and interpretations that have been issued by the Malaysian Accounting Standard Board (“**MASB**”) where the effective has been deferred to a date to be determined by MASB and have not been applied by the Group:

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THIRD (3RD) QUARTER ENDED 30 SEPTEMBER 2025 (CONT'D)**

**A. EXPLANATORY NOTES TO THE UNAUDITED CONSOLIDATED INTERIM FINANCIAL REPORT FOR THE THIRD (3RD) QUARTER ENDED 30 SEPTEMBER 2025 (CONT'D)**

**A1. Accounting policies and methods of computation (Cont'd)**

**Standards issued but not yet effective (Cont'd):**

		<b>Effective dates for financial periods beginning on or after</b>
Amendments to MFRS 1, MFRS 7, MFRS 9, MFRS 10 and MFRS 107	Annual Improvement to MFRS Accounting Standards – Volume 11	1 January 2026
Amendments to MFRS 9 and MFRS 7	Classification and Measurement of Financial Instruments	1 January 2026
Amendments to MFRS 9 and MFRS 7	Contract Referencing Nature-dependent Electricity	1 January 2026
MFRS 18	Presentation and Disclosure in Financial Statements	1 January 2027
MFRS 19	Subsidiaries without Public Accountability; Disclosure	1 January 2027
Amendments to MFRS 10 and MFRS 128	Consolidated Financial Statements and Investments in Associates and Joint Ventures - Sale or Contribution of Assets between an Investor and its Associate or Joint Venture	Deferred

**A2. Auditors' report of preceding annual financial statements**

There was no qualification to the audited consolidated financial statements of the Company for the FYE 31 December 2024.

**A3. Seasonal or cyclical factors**

The Group's operations are not subject to any significant seasonal or cyclical factors.

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THIRD (3RD) QUARTER ENDED 30 SEPTEMBER 2025 (CONT'D)**

**A. EXPLANATORY NOTES TO THE UNAUDITED CONSOLIDATED INTERIM FINANCIAL REPORT FOR THE THIRD (3RD) QUARTER ENDED 30 SEPTEMBER 2025 (CONT'D)**

**A4. Unusual items**

There were no unusual items affecting assets, liabilities, equity, net income or cash flows of the Group during the current quarter and financial period-to-date.

**A5. Material changes in estimates**

There were no material changes in estimates of amounts reported in prior interim periods or prior year that would have a material effect on the current quarter's results.

**A6. Debt and equity securities**

There was no other issuance, cancellation, repurchase, resale and repayment of debt and equity securities for the current financial period-to-date.

**A7. Segmental information**

The Group's revenue based on the geographical location of its customers is presented as follows:

	Current quarter ended		Financial period-to-date	
	Unaudited 30 Sep 2025 RM'000	Unaudited 30 Sep 2024 RM'000	Unaudited 30 Sep 2025 RM'000	Unaudited 30 Sep 2024 RM'000
Malaysia	2,838	8,539	7,855	23,261
China	1	26,297	41	41,656
Others	121	98	341	201
<b>Total</b>	<b>2,960</b>	<b>34,934</b>	<b>8,237</b>	<b>65,118</b>

The Group has reinforced its core strength by channelling its resources in the manufacturing of health supplement and functional food products, with emphasis on in-demand health categories such as anti-ageing, immunity and other benefits that drives market demand. Efforts taken include communicating with local prospective customers since the cessation of China supply contracts recently, as well as to provide new product development to current existing customers.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THIRD (3RD) QUARTER ENDED 30 SEPTEMBER 2025 (CONT'D)

A. EXPLANATORY NOTES TO THE UNAUDITED CONSOLIDATED INTERIM FINANCIAL REPORT FOR THE THIRD (3RD) QUARTER ENDED 30 SEPTEMBER 2025 (CONT'D)

A8. Valuation of property, plant and equipment

The Group has not carried out any valuation of its property, plant and equipment in the current quarter.

A9. Capital commitments

	Unaudited Current quarter ended 30 Sep 2025 RM'000	Audited Financial year-to- date 31 Dec 2024 RM'000
<b>Authorised and contracted for:</b>		
Purchase of property, plant and equipment	4,500	4,500

A10. Changes in the composition of the Group

On 1 January 2025, Mediconstant Holding Sdn Bhd ceased to be a subsidiary of Botanical Distribution Sdn Bhd following the disposal of its 100% equity interest comprising 5,150,000 ordinary shares for a total cash consideration of RM180,000/=.

Other than the above, there were no other major changes in the composition of the Group during the period ending 31 December 2025.

A11. Contingent liabilities

	Unaudited Current quarter ended 30 Sep 2025 RM'000	Audited Financial year-to- date 31 Dec 2024 RM'000
<b>Unsecured:</b>		
Performance bonds in relation to the management of Herbal Integrated Cluster Development	200	200

**BIOALPHA HOLDINGS BERHAD** (Registration No: 201101021398 (949536-X))

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THIRD (3RD) QUARTER ENDED 30 SEPTEMBER 2025 (CONT'D)**

**A. EXPLANATORY NOTES TO THE UNAUDITED CONSOLIDATED INTERIM FINANCIAL REPORT FOR THE THIRD (3RD) QUARTER ENDED 30 SEPTEMBER 2025 (CONT'D)**

**A12. Material events subsequent to the end of the quarter**

There were no other material events subsequent to the end of the current quarter and financial period-to-date that have not been reflected in this interim financial report.

**A13. Related party transactions**

There was no additional related party transaction entered into with related parties during the current financial quarter.

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THIRD (3RD) QUARTER ENDED 30 SEPTEMBER 2025 (CONT'D)**

**B1. Analysis of performance**

The Group's current quarter revenue for the financial period ended 30 September 2025 ("3QFY25") dropped by 91.4% year-on-year ("YoY") to RM3.0 million, as compared to RM34.9 million in the preceding year's corresponding quarter ("3QFY24"). The softer performance was primarily due to contract cessation of the Group's supply of health foods operations in China, and disposal of retail pharmacies business recently.

In 3QFY25, revenue for our manufacturing operations increased by 11.1% year-on-year ("YoY") to RM3.0 million (3QFY24: RM2.7 million). Specifically, domestic manufacturing turnover increased by 7.7% YoY to RM2.8 million (3QFY24: RM2.6 million).

In 3QFY25, no revenue was recorded for the Group's supply of health foods business to China, against RM26.3 million in 3QFY24, mainly due to the cessation of the health food supply contract with the China counterparts.

In 3QFY25, no revenue was recorded for the retail pharmacy division, compared with RM5.9 million in 3QFY24, as the Company have disposed retail pharmacy business in January 2025.

During the quarter under review, the Group's gross loss amounted to RM0.1 million, compared to a gross profit of RM0.1 million in 3QFY24. Consequently, net loss attributable to the owners of the parent ("net loss") decreased to RM4.8 million in 3QFY25 (3QFY24: net loss of RM5.6million).

However, the Group also recognised a net loss on impairment of financial assets of RM1.5 million in 3QFY25.

**Comparison with immediate preceding quarter's results**

The Group's revenue for the 3QFY25, contributed solely from manufacturing had increased to RM3.0 million, against RM2.8 million in the second (2nd) quarter ended 30 June 2025. The increase is the result of orders from new customers during the quarter, as the Company continue to introduce new products that meet the market's evolving needs.

Net loss for 3QFY25 dropped to RM4.8 million from RM9.4 million in the preceding quarter, primarily due to a lower fair value loss on quoted shares investment during this quarter as compared with the 2QFY25.

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THIRD (3RD) QUARTER ENDED 30 SEPTEMBER 2025 (CONT'D)**

**B2. Prospects for the financial year ending 31 December 2025**

The global economic climate for 2025 remains complex, with heightened geopolitical tensions and lingering economic uncertainties. Nonetheless, the gradual easing of inflationary pressures suggests a potential path towards recovery.

At Bioalpha, we continue to focus on our business strategies, and on optimising costs to navigate external headwinds and seize emerging opportunities.

Agriculture remains an important part of Bioalpha as the Company shall focus more on both farms in Terengganu and Johor to produce high quality agro-products to customers and to supply our manufacturing arm.

Bioalpha remains committed to focus on its manufacturing operations, especially on the domestic front, by leveraging resources to expand our offerings with products promising benefit that are in high market demand. At the same time, we are working to secure additional new customers.

Bioalpha is also embarking on the development of an 8-acre agro park in Langkawi, Kedah. This project aims to boost agro-tourism in the region and generate new revenue streams for Bioalpha through the commercialization of high-value herbal products. Development has already commenced, with a targeted opening within the next three years.

As we navigate through 2025, the Group shall stay adaptable and resolute in carrying out our strategic initiatives, while maintaining cost efficiency. All in all, we believe that FY2025 performance to be supported by positive contributions from all our segments, barring unforeseen circumstances.

**B3. Profit forecast or profit guarantee**

The Group has not issued any profit forecast or profit guarantee in any public documents.

**B4. Foreign Exchange Exposure / Hedging policy**

The Group is exposed to foreign currency risk on transactions that are denominated in currencies other than the respective functional currencies of Group entities. The currencies giving rise to this risk are United States Dollar (“USD”), Chinese Renminbi (“CNY”), Hong Kong Dollar (“HKD”), Indonesian Rupiah (“IDR”) and Singapore Dollar (“SGD”).

The Group have not entered into any derivative instruments for hedging or trading purposes as the net exposure to foreign currency risk is not significant. However, the exposure to foreign currency risk is monitored from time to time by management.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THIRD (3RD) QUARTER ENDED 30 SEPTEMBER 2025 (CONT'D)

B5. Taxation

	Current quarter ended		Financial period-to-date	
	Unaudited 30 Sep 2025 RM'000	Unaudited 30 Sep 2024 RM'000	Unaudited 30 Sep 2025 RM'000	Unaudited 30 Sep 2024 RM'000

Tax expense recognised in profit or loss:

- Current tax provision	-	1	-	1
-------------------------	---	---	---	---

Effective tax rate (%)	-	-	-	-
------------------------	---	---	---	---

Bioalpha East Coast Agro Sdn Bhd (“**BECASB**”), a wholly-owned subsidiary of the Group, was awarded a tax incentive by the Malaysian Investment Development Authority, which grants BECASB a 100% tax exemption on income for a period of ten (10) years after commercial production date is determined by the relevant authorities.

Bioalpha R&D Sdn Bhd (“**BRDSB**”), a wholly-owned subsidiary of the Group, was awarded BioNexus Status by the Malaysian Bioeconomy Development Corporation Sdn Bhd, which grants BRDSB a 100% tax exemption on income from qualifying activities for a period of ten (10) years ended 30 June 2018 and 20% concessionary tax rate on statutory income for a further ten (10) years, from the financial year ended 2023 to 2032.

Bioalpha (Johor Herbal) Sdn Bhd (“**BJHSB**”), a subsidiary of the Group, was awarded an incentive by Ministry of Agriculture and Agro-Based Industry Malaysia, which allows BJHSB to enjoy 100% tax exemption on income for a period of ten (10) years commencing from 1 January 2018.

Bioalpha (Hainan) Health Biotechnology Ltd (“**BHHBL**”), a subsidiary of the Group which was incorporated in China is taxed at the statutory rate of 15% on its chargeable incomes.

Meanwhile, the Group’s other subsidiaries are taxed at the statutory rate of 24% on their chargeable incomes.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THIRD (3RD) QUARTER ENDED 30 SEPTEMBER 2025 (CONT'D)

**B6. Trade receivables**

	Unaudited 30 Sep 2025 RM'000
Trade receivables	6,419
Less: Accumulated impairment losses	(5,007)
	<u>1,412</u>

The Group's normal trade credit terms ranged from 30 to 180 days. Other credit terms are assessed and approved on a case-to-case basis. Trade receivables are recognised at their original invoice amounts which represent their fair value on initial recognition.

**B7. Borrowings**

The Group's borrowings as at 30 September 2025 are as follows:

	Short term RM'000	Long term RM'000	Total RM'000
<b>Secured</b>			
Bankers' acceptance	217	-	217
Term loans	107	514	621
<b>Total bank borrowings</b>	<u>324</u>	<u>514</u>	<u>838</u>

All the borrowings were secured and denominated in Ringgit Malaysia.

**B8. Material litigation**

As at the date of this report, there is no litigation or arbitration, which has a material effect on the financial position of the Group, and the Board is not aware of any other proceedings pending or threatened or of any fact likely to give rise to any other proceedings.

**B9. Dividends**

The Board did not recommend any dividend during the financial period ended ("FPE") 30 September 2025 (FYE 31 December 2024: Nil).

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THIRD (3RD) QUARTER ENDED 30 SEPTEMBER 2025 (CONT'D)

**B10. Loss per share**

The basic loss per share is calculated as follows:

	Current quarter ended		Financial period-to-date	
	Unaudited 30 Sep 2025 RM'000	Unaudited 30 Sep 2024 RM'000	Unaudited 30 Sep 2025 RM'000	Unaudited 30 Sep 2024 RM'000
Net loss attributable to owners of the parent	(4,820)	(5,597)	(19,633)	(19,888)
Weighted average number of ordinary shares in issue ('000)	1,406,494	1,406,491	1,406,492	1,406,491
Basic loss per share (sen)	<u>(0.343)</u>	<u>(0.398)</u>	<u>(1.396)</u>	<u>(1.414)</u>

The diluted loss per share is calculated as follows:

	Current quarter ended		Financial period-to-date	
	Unaudited 30 Sep 2025 RM'000	Unaudited 30 Sep 2024 RM'000	Unaudited 30 Sep 2025 RM'000	Unaudited 30 Sep 2024 RM'000
Net loss attributable to owners of the parent	(4,820)	(5,597)	(19,633)	(19,888)
Weighted average number of ordinary shares in issue ('000)	1,412,719	1,546,900	1,412,717	1,546,900
Diluted loss per share (sen)	<u>(0.312)</u>	<u>(0.362)</u>	<u>(1.269)</u>	<u>(1.286)</u>

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THIRD (3RD) QUARTER ENDED 30 SEPTEMBER 2025 (CONT'D)**

**B11. Disclosure on selected expense/(income) items as required by the Listing Requirements**

Included in loss before taxation are the following expense/(income) items:

	Current quarter ended		Financial period-to-date	
	Unaudited 30 Sep 2025 RM'000	Unaudited 30 Sep 2024 RM'000	Unaudited 30 Sep 2025 RM'000	Unaudited 30 Sep 2024 RM'000
Allowance for expected credit losses on other receivables	-	64	-	-
Bad debts written off	-	-	-	7,015
Deposit written off	-	-	11	-
Depreciation and amortisation expenses	1,417	2,961	4,938	8,545
Fair value (gain)/loss on:				
- Biological assets	(37)	-	(75)	(19)
- Quoted shares investments	1,567	2,204	11,641	6,440
Gain on disposal of property, plant and equipment	-	(1,759)	(119)	(1,810)
Gain on disposal of subsidiary	-	-	(865)	(44)
(Gain)/Loss on foreign exchange				
- Realised	-	-	(2)	5
- Unrealised	(1)	192	(14)	210
Impairment loss on intangible assets	1,318	-	1,318	-
Impairment loss on investment in associates	23	-	23	-
Impairment loss on property, plant and equipment	-	843	-	843
Property, plant and equipment written off	80	-	115	-
Provision of slow-moving inventories	-	77	-	-
Reversal of impairment losses on:				
- Trade receivables	(8)	-	(193)	(6,725)
- Other receivables	(59)	(80)	(59)	(271)
Reversal of provision of slow-moving inventories	-	-	-	(533)
Interest expenses	48	123	202	442
Interest income	(7)	(52)	(57)	(186)
Inventories written off	-	(57)	-	552

There was no provision for gain or loss on disposal of properties and exceptional items for the current quarter and financial period-to-date.

**BIOALPHA HOLDINGS BERHAD (Registration No: 201101021398 (949536-X))**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THIRD (3RD) QUARTER ENDED 30 SEPTEMBER 2025 (CONT'D)**

**C. AUTHORISATION FOR ISSUE**

The interim financial report was authorised for issue by the Board in accordance with a resolution of the Board dated 26 November 2025.

By Order of the Board,

**Tan Tong Lang (MAICSA 7045482)**

**Thien Lee Mee (LS0010621)**

Company Secretaries

Kuala Lumpur

Dated: 26 November 2025